Connor Clark & Lunn Investment Management Ltd. Makes New $353,000 Investment in Cerus Co. (NASDAQ:CERS)

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Cerus Co. (NASDAQ:CERS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 202,613 shares of the biotechnology company’s stock, valued at approximately $353,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Hood River Capital Management LLC increased its position in Cerus by 390.4% in the 2nd quarter. Hood River Capital Management LLC now owns 1,469,754 shares of the biotechnology company’s stock valued at $2,587,000 after acquiring an additional 1,170,060 shares during the period. Easterly Investment Partners LLC grew its stake in shares of Cerus by 726.1% in the third quarter. Easterly Investment Partners LLC now owns 313,522 shares of the biotechnology company’s stock worth $546,000 after purchasing an additional 275,569 shares in the last quarter. Bouvel Investment Partners LLC increased its holdings in shares of Cerus by 87.1% during the third quarter. Bouvel Investment Partners LLC now owns 505,020 shares of the biotechnology company’s stock valued at $879,000 after purchasing an additional 235,082 shares during the period. Sei Investments Co. raised its stake in shares of Cerus by 658.9% during the second quarter. Sei Investments Co. now owns 263,839 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 229,074 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in Cerus by 938.5% in the second quarter. AQR Capital Management LLC now owns 215,901 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 195,112 shares during the period. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Stifel Nicolaus lowered their target price on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th.

Insider Activity

In related news, CFO Kevin Dennis Green sold 28,385 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the sale, the chief financial officer now directly owns 590,365 shares in the company, valued at $1,286,995.70. The trade was a 4.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 3.40% of the company’s stock.

Cerus Stock Performance

Shares of NASDAQ CERS opened at $1.85 on Friday. Cerus Co. has a 1 year low of $1.38 and a 1 year high of $2.59. The firm has a market cap of $343.56 million, a P/E ratio of -16.82 and a beta of 1.20. The stock has a fifty day moving average price of $1.74 and a two-hundred day moving average price of $1.92. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.